Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
Why the Middle East is being left behind by global climate finance plans 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Investors value green labels — but not always for the right reasons 
How the UK’s rollback of banking regulations could risk another financial crisis 
Citi Raises TSMC Price Target as AI Chip Demand Strengthens Growth Outlook 
Infosys Shares Drop Amid Earnings Quality Concerns 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Ferrari Group to Launch IPO in Amsterdam, Targets Over $1 Billion Valuation 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
